Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 9/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217263 | 0.88 | MAPK14 (0.44) | MAPK14CHEK1MAPK1BCHEACHE | |
| SCHEMBL2215356 | 0.88 | ACHE (0.49) | TRPA1MAPK14CHEK1HSP90AB1MAPK1 | |
| SCHEMBL2217915 | 0.86 | KDM4E (0.47) | TRPA1MAPK14CHEK1BCHEACHE | |
| SCHEMBL2217969 | 0.85 | TRPA1 (0.56) | TRPA1EGLN1MAPK14MAPK1 | |
| SCHEMBL2215293 | 0.85 | MAPK14 (0.44) | TRPA1MAPK14CHEK1BCHEACHE | |
| SCHEMBL2215777 | 0.82 | MAPK14 (0.41) | MAPK14CHEK1HSP90AB1MAPK1BCHE | |
| SCHEMBL2216227 | 0.81 | MAPT (0.42) | MAPK14CHEK1 | |
| SCHEMBL2216299 | 0.80 | GSK3A (0.46) | MAPK14 | |
| SCHEMBL5563411 | 0.79 | KDM4E (0.47) | TRPA1MAPK14CHEK1BCHEACHE | |
| SCHEMBL4352449 | 0.77 | KDM4E (0.51) | TRPA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | TRPA1 3678/4885EGLN1 2796/4885MAPK14 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.